Servier’s Olivier Laureau: Change Instigator
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world…
InFocus
EUROPEAN MID-CAPS
European MidPharmas: Focused and Resilient, yet Vulnerable
European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off their inherent vulnerabilities according to a new report from specialist pharma and biotech consultancy Novasecta. Focus 75…
READ MORE
Swiss Mid-Caps and Minnows: At the Vanguard of Creativity
In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized…
Spanish Mid-Caps: Going Global
Despite the Spanish economy and pharmaceutical market’s steady growth, many local players are becoming cognizant…
5 Top European Mid-Cap CEOs To Know
Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The…
Top European Pharma Mid-Cap Ranking 2019
The European MidPharma Performance Ranking 2019 is taken from The Novasecta European Midpharma Report 2019, which…
Pierre Fabre: Medicalization, Convergence & the Rise of…
Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics…
More on European Mid-Caps
Markus Sieger – CEO, Polpharma
Markus Sieger, CEO of Polpharma, outlines his global strategy for the company,…
Antonio Portela – CEO, Bial
Antonio Portela, seven years into leading the Bial operation in Portugal, shares…
Gilles Pluntz – Chairman of the Group Operating…
The Chairman of Ferring’s Group Operating Committee and Senior Vice President…
David Meek – CEO, Ipsen, France
Ipsen global CEO David Meek provides a fascinating look into the French…
Denis Delval – CEO, LFB, France
Denis Delval, CEO of iconic French pharma firm LFB since December 2017,…
Esteve: Out with the Old; In with the New
Esteve has long been a family-run business, though in early 2018 the Spanish…
More InFocus
